> top > docs > PubMed:33089863 > annotations

PubMed:33089863 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 87-92 Body_part denotes Bowel http://purl.org/sig/ont/fma/fma7199
T2 430-435 Body_part denotes bowel http://purl.org/sig/ont/fma/fma7199

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 38-46 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 47-56 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T3 74-101 Disease denotes Inflammatory Bowel Diseases http://purl.obolibrary.org/obo/MONDO_0005265
T4 207-231 Disease denotes coronavirus disease 2019 http://purl.obolibrary.org/obo/MONDO_0100096
T5 233-241 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 359-367 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 417-443 Disease denotes inflammatory bowel disease http://purl.obolibrary.org/obo/MONDO_0005265
T8 445-448 Disease denotes IBD http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265
T10 524-527 Disease denotes IBD http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265
T12 627-635 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 693-740 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T14 693-726 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T15 838-846 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T16 894-897 Disease denotes IBD http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265
T18 928-936 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T19 991-994 Disease denotes IBD http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265
T21 1021-1029 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T22 1043-1051 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T23 1304-1312 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T24 1385-1392 Disease denotes obesity http://purl.obolibrary.org/obo/MONDO_0011122
T25 1430-1438 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T26 1583-1590 Disease denotes obesity http://purl.obolibrary.org/obo/MONDO_0011122
T27 1655-1663 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T28 1664-1673 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T29 1771-1779 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T30 1829-1832 Disease denotes IBD http://purl.obolibrary.org/obo/MONDO_0005052|http://purl.obolibrary.org/obo/MONDO_0005265

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 243-246 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T2 371-372 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 483-485 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T4 647-648 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 684-688 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T6 877-878 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 1413-1414 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T8 1783-1784 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 324-339 Chemical denotes immunomodulator http://purl.obolibrary.org/obo/CHEBI_50846

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 74-101 Phenotype denotes Inflammatory Bowel Diseases http://purl.obolibrary.org/obo/HP_0002037
T2 417-443 Phenotype denotes inflammatory bowel disease http://purl.obolibrary.org/obo/HP_0002037
T3 445-448 Phenotype denotes IBD http://purl.obolibrary.org/obo/HP_0002037
T4 524-527 Phenotype denotes IBD http://purl.obolibrary.org/obo/HP_0002037
T5 894-897 Phenotype denotes IBD http://purl.obolibrary.org/obo/HP_0002037
T6 991-994 Phenotype denotes IBD http://purl.obolibrary.org/obo/HP_0002037
T7 1385-1392 Phenotype denotes obesity http://purl.obolibrary.org/obo/HP_0001513
T8 1583-1590 Phenotype denotes obesity http://purl.obolibrary.org/obo/HP_0001513
T9 1829-1832 Phenotype denotes IBD http://purl.obolibrary.org/obo/HP_0002037

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
4 38-46 Disease denotes COVID-19 MESH:C000657245
5 47-56 Disease denotes Infection MESH:D007239
6 60-68 Species denotes Patients Tax:9606
7 74-101 Disease denotes Inflammatory Bowel Diseases MESH:D015212
37 201-226 Disease denotes novel coronavirus disease MESH:C000657245
38 233-241 Disease denotes COVID-19 MESH:C000657245
39 359-367 Disease denotes COVID-19 MESH:C000657245
40 403-411 Species denotes patients Tax:9606
41 417-443 Disease denotes inflammatory bowel disease MESH:D015212
42 445-448 Disease denotes IBD MESH:D015212
43 474-482 Species denotes patients Tax:9606
44 524-527 Disease denotes IBD MESH:D015212
45 627-635 Disease denotes COVID-19 MESH:C000657245
46 693-740 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
47 838-846 Disease denotes COVID-19 MESH:C000657245
48 894-897 Disease denotes IBD MESH:D015212
49 898-906 Species denotes patients Tax:9606
50 928-936 Disease denotes COVID-19 MESH:C000657245
51 991-994 Disease denotes IBD MESH:D015212
52 995-1003 Species denotes patients Tax:9606
53 1021-1029 Disease denotes COVID-19 MESH:C000657245
54 1043-1051 Disease denotes COVID-19 MESH:C000657245
55 1072-1080 Species denotes patients Tax:9606
56 1304-1312 Disease denotes COVID-19 MESH:C000657245
57 1385-1392 Disease denotes obesity MESH:D009765
58 1430-1438 Disease denotes COVID-19 MESH:C000657245
59 1562-1567 Disease denotes death MESH:D003643
60 1583-1590 Disease denotes obesity MESH:D009765
61 1655-1663 Disease denotes COVID-19 MESH:C000657245
62 1664-1673 Disease denotes infection MESH:D007239
63 1771-1779 Disease denotes COVID-19 MESH:C000657245
64 1815-1823 Species denotes patients Tax:9606
65 1829-1832 Disease denotes IBD MESH:D015212

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-102 Sentence denotes Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
T2 103-114 Sentence denotes BACKGROUND:
T3 115-268 Sentence denotes The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established.
T4 269-450 Sentence denotes We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).
T5 451-459 Sentence denotes METHODS:
T6 460-587 Sentence denotes We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020.
T7 588-741 Sentence denotes The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2.
T8 742-864 Sentence denotes Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.
T9 865-873 Sentence denotes RESULTS:
T10 874-937 Sentence denotes In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19.
T11 938-1030 Sentence denotes There was no difference in age, sex, or race between IBD patients with and without COVID-19.
T12 1031-1170 Sentence denotes The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55).
T13 1171-1368 Sentence denotes After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63).
T14 1369-1495 Sentence denotes The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47).
T15 1496-1568 Sentence denotes There were 7 hospitalizations, 3 intensive care unit stays, and 1 death.
T16 1569-1674 Sentence denotes Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.
T17 1675-1687 Sentence denotes CONCLUSIONS:
T18 1688-1833 Sentence denotes The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD.
T1 0-102 Sentence denotes Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
T2 103-114 Sentence denotes BACKGROUND:
T3 115-268 Sentence denotes The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established.
T4 269-450 Sentence denotes We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).
T5 451-459 Sentence denotes METHODS:
T6 460-587 Sentence denotes We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020.
T7 588-741 Sentence denotes The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2.
T8 742-864 Sentence denotes Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.
T9 865-873 Sentence denotes RESULTS:
T10 874-937 Sentence denotes In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19.
T11 938-1030 Sentence denotes There was no difference in age, sex, or race between IBD patients with and without COVID-19.
T12 1031-1170 Sentence denotes The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55).
T13 1171-1368 Sentence denotes After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63).
T14 1369-1495 Sentence denotes The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47).
T15 1496-1568 Sentence denotes There were 7 hospitalizations, 3 intensive care unit stays, and 1 death.
T16 1569-1674 Sentence denotes Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.
T17 1675-1687 Sentence denotes CONCLUSIONS:
T18 1688-1833 Sentence denotes The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD.

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-102 Sentence denotes Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
T2 103-114 Sentence denotes BACKGROUND:
T3 115-268 Sentence denotes The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established.
T4 269-450 Sentence denotes We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).
T5 451-459 Sentence denotes METHODS:
T6 460-587 Sentence denotes We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020.
T7 588-741 Sentence denotes The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2.
T8 742-864 Sentence denotes Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.
T9 865-873 Sentence denotes RESULTS:
T10 874-937 Sentence denotes In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19.
T11 938-1030 Sentence denotes There was no difference in age, sex, or race between IBD patients with and without COVID-19.
T12 1031-1170 Sentence denotes The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55).
T13 1171-1368 Sentence denotes After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63).
T14 1369-1495 Sentence denotes The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47).
T15 1496-1568 Sentence denotes There were 7 hospitalizations, 3 intensive care unit stays, and 1 death.
T16 1569-1674 Sentence denotes Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.
T17 1675-1687 Sentence denotes CONCLUSIONS:
T18 1688-1833 Sentence denotes The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD.